The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...

Therapeutic landscape of Rad51 in cancer treatment. Key elements include (1) DNA damage sources (PARPi, chemo/radiotherapy);(2) repair pathways (Rad51‐mediated HR); (3) intervention strategies (Rad51 ...

New research reveals that triggering a cell’s DNA damage response could be a promising avenue for developing novel treatments against several rare but devastating viruses for which no antiviral ...

The armamentarium of prostate cancer therapies expanded in 2020 to include the first genomically targeted agents. Men with both somatic and germline alterations in the DNA damage repair (DDR) pathway, ...

Researchers have discovered how cells activate a last-resort DNA repair system when severe damage strikes. When genetic ...

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...